Evidence map›Paper›PMID 41196649›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2026

Fibroblast Growth Factor 23, Urinary Phosphate, and Risk of Progression of CKD.

Takaaki Kosugi, Masahiro Eriguchi, Hiroyuki Tamaki, Riri Furuyama, Mari Nakanishi, Takayuki Uemura, Hikari Tasaki, Masatoshi Nishimoto, Kaori Tanabe, Keisuke Okamoto and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Takaaki KosugiDepartment of Nephrology, Nara Medical University, Nara, Japan.ORCID 0000-0003-3696-2263
Masahiro EriguchiDepartment of Nephrology, Nara Medical University, Nara, Japan.ORCID 0000-0001-8422-7314
Hiroyuki TamakiDepartment of Nephrology, Nara Medical University, Nara, Japan.
Riri FuruyamaDepartment of Nephrology, Nara Medical University, Nara, Japan.
Mari NakanishiV-iCliniX Laboratory, Nara Medical University, Nara, Japan.ORCID 0000-0002-9242-4980
Takayuki UemuraDepartment of Nephrology, Nara Medical University, Nara, Japan.
Hikari TasakiDepartment of Nephrology, Nara Medical University, Nara, Japan.
Masatoshi NishimotoDepartment of Nephrology, Nara Medical University, Nara, Japan.ORCID 0009-0006-2063-781
Kaori TanabeDepartment of Nephrology, Nara Medical University, Nara, Japan.ORCID 0000-0002-6553-7314
Keisuke OkamotoDepartment of Nephrology, Nara Medical University, Nara, Japan.ORCID 0000-0003-1862-8640
Masaru MatsuiDepartment of Nephrology, Nara Medical University, Nara, Japan.
Ken-Ichi SamejimaDepartment of Nephrology, Nara Medical University, Nara, Japan.
Makoto WatanabeDepartment of Cardiovascular Medicine, Nara Medical University, Nara, Japan.
Yoshihiko SaitoDepartment of Cardiovascular Medicine, Nara Medical University, Nara, Japan.ORCID 0000-0001-5574-3571
Kazuhiko TsuruyaDepartment of Nephrology, Nara Medical University, Nara, Japan.ORCID 0000-0002-8390-2928

Funding

Innovative Science and Technology Initiative for Security, Nakatani Foundation JPJ004596
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biomarkersCKDcohort studiesepidemiology and outcomeshyperphosphatemia

Identifiers

PMID41196649
PMCPMC12889974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.